Adam J. Townsend - 05 Dec 2022 Form 4 Insider Report for Apellis Pharmaceuticals, Inc. (APLS)

Role: Chief Commercial Officer
Signature: /s/ David Watson, attorney-in-fact for Adam Townsend
Issuer symbol: APLS
Transactions as of: 05 Dec 2022
Net transactions value: -$327,350
Form type: 4
Filing time: 07 Dec 2022, 07:30:09 UTC
Previous filing: 07 Nov 2022
Next filing: 05 Jan 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	APLS	Common Stock	Options Exercise	$75,450	-5,000	-9.5%	$15.09	47,907	05 Dec 2022	Direct	F1
transaction	APLS	Common Stock	Sale	$251,900	-5,000	-10%	$50.38	42,907	05 Dec 2022	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	APLS	Stock Option (Right to Buy)	Options Exercise	$0	-5,000	-1.6%	$0.000000	307,500	05 Dec 2022	Common Stock	5,000	$15.09	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The sales reported on this Form 4 were effected by pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 10, 2022.
F2	This stock option was granted on 11/16/2018 and is fully vested.